OncoOne’s Post

🧬🔬 Dr. Ping Mu and his team unveil pivotal findings in prostate cancer research, identifying genes ZNF397 and TET2 as key factors in therapy resistance due to lineage plasticity. Published in Cancer Discovery, their study reveals how these genes help cancer cells evade standard treatments, presenting a new target for innovative therapies. These insights deepen our understanding of drug resistance mechanisms and pave the way for drugs that could reverse resistance in advanced prostate cancer cases. #CancerResearch #ProstateCancer #TherapyResistance #MedicalInnovation Read more: https://lnkd.in/d5fRVgJW

The Oncolines® team want to take a moment to share with you an article that provides insight in their work. We READcommend our article in Frontiers in Oncology on cell panel profiling and biochemical profiling of kinase inhibitors. A must-read for anyone passionate about advancing cancer research and targeted therapies. Check it out here: https://lnkd.in/eyVA8GEe #CancerResearch #Oncolines #READcommendation

Shout out to Drs. Nelson and Subbiah for their astutely written reply to the Conley et al. editorial on the “adscopal effect” in the high-impact journal, Molecular Cancer Therapeutics. Read it here: https://bit.ly/3SqI55Y   An “abscopal effect” classically refers to the regression of distant tumors outside the treatment field of radiation therapy. By contrast, the “adscopal effect," a term coined by Conley et al. describes the shrinkage of distant, noninjected visceral lesions mediated by the oncolytic adenovirus, AdAPT-001.   As Nelson and Subbiah point out, what differentiates oncolytic adenoviruses like AdAPT-001 from other oncolytic viruses is that they “piggyback” on lymphocytes and erythrocytes, which are thought to shield them from the presence of neutralizing antibodies so that these adenoviruses reach and transduce non-injected tumors.   Our expectation is that if AdAPT-001 continues to make waves in hard-to-treat tumors like sarcomas, the novel term “adscopal effect” will become conventionalized and formally enter the clinical lexicon.  

My first publication β-Arrestin inhibition induces autophagy, apoptosis, G0/G1 cell cycle arrest in agonist-activated V2R receptor in breast cancer cells https://lnkd.in/dxT2pkEK

🔬 Insights from ASCO 2024! Dr Antonio Marra from the European Institute of Oncology discusses cyclin-E1 amplification in advanced breast cancer. This subset of patients shows poor outcomes with standard therapies but promising responses with PKMYT1 and CDK-2 inhibitors in preclinical models. Learn about the potential for new targeted treatments. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #BreastCancer #OncologyInnovation #CyclinE1

Exciting News! I'm pleased to share that the latest manuscript from the ECPL, titled "Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen," has been published in Cancer Research Communications. This paper focuses on the interaction between tyrosine kinase inhibitors and OATP1B1, contributing to a deeper understanding of their role in cancer treatment. I want to extend my gratitude to my co-authors and colleagues who were instrumental in bringing this work to life! For those interested in the full details, check out the article here: https://lnkd.in/gqHkSY5W. #CancerResearch #Oncology #Pharmacology #ScientificResearch #JournalPublication

Our [KD Validated] Heme Oxygenase 1 (HO-1/HMOX1) Rabbit mAb has been featured in different studies, including a high-impact research article (IF 37.300) on overcoming resistance in lung adenocarcinoma. The study, "Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance," demonstrated that targeting HO-1, along with METTL7B, could play a vital role in re-sensitizing drug-resistant cancer cells. This makes our antibody (A19062) an invaluable asset for researchers investigating resistance mechanisms in cancer therapy. Discover what ABclonal can offer your research. Read the research if you're interested: https://hubs.li/Q02TQqKR0

Antibody-drug conjugate: the “biological missile” for targeted cancer therapy. Herein, researchers conducted a review of the history and general mechanism of action of Antibody–drug conjugates (ADCs), and then briefly discussed the molecular aspects of key components of ADCs and the mechanisms by which these key factors influence the activities of ADCs. https://hubs.ly/Q02vrrjz0

📣 Exciting CUTANA CUT&Tag application! Here, EpiCypher pAG-Tn5 and CUT&Tag protocol were used to study localization of cGAS in cancer cells, which helped uncover novel connections between SWI/SNF chromatin remodelers and mTORC2 signaling in chemoresistant colorectal cancer. These results provide promising new strategies for therapeutic development! https://hubs.la/Q02KB1cn0

Find out more in the September issue of Cancer Discovery! AACR Journals